{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:57:25Z","timestamp":1778698645403,"version":"3.51.4"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T00:00:00Z","timestamp":1562976000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T00:00:00Z","timestamp":1562976000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11899-019-00536-6","type":"journal-article","created":{"date-parts":[[2019,7,13]],"date-time":"2019-07-13T22:33:43Z","timestamp":1563057223000},"page":"414-425","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["IMiDs New and Old"],"prefix":"10.1007","volume":"14","author":[{"given":"Samuel","family":"Yamshon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,13]]},"reference":[{"issue":"9","key":"536_CR1","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D\u2019Amato","year":"1994","unstructured":"D\u2019Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91(9):4082\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"536_CR2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/sj.bjc.6690020","volume":"79","author":"HM Verheul","year":"1999","unstructured":"Verheul HM, Panigrahy D, Yuan J, D\u2019Amato RJ. Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits. Br J Cancer. 1999;79(1):114\u20138.","journal-title":"Br J Cancer"},{"key":"536_CR3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/nrc1323","volume":"4","author":"JB Bartlett","year":"2004","unstructured":"Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314\u201322.","journal-title":"Nat Rev Cancer"},{"key":"536_CR4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","volume":"163","author":"LG Corral","year":"1999","unstructured":"Corral LG, Haslett PAJ, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163:380\u20136.","journal-title":"J Immunol"},{"issue":"1\u20132","key":"536_CR5","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.mvr.2005.01.002","volume":"69","author":"K Dredge","year":"2005","unstructured":"Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res. 2005;69(1\u20132):56\u201363.","journal-title":"Microvasc Res"},{"key":"536_CR6","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1158\/0008-5472.CAN-13-0750","volume":"73","author":"K Song","year":"2013","unstructured":"Song K, Herzog B, Sheng M, Fu J, Mcdaniel J, Chen H, et al. Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma. Cancer Res. 2013;73:7254\u201364.","journal-title":"Cancer Res"},{"key":"536_CR7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1053\/j.seminoncol.2005.06.018","volume":"32","author":"R Knight","year":"2005","unstructured":"Knight R. IMiDs: a novel class of immunomodulators. Semin Oncol. 2005;32:24\u201330.","journal-title":"Semin Oncol"},{"issue":"21","key":"536_CR8","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","volume":"114","author":"AG Ramsay","year":"2009","unstructured":"Ramsay AG, Clear AJ, Kelly G, Fatah R, Matthews J, MacDougall F, et al. Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy. Blood. 2009;114(21):4713\u201320.","journal-title":"Blood."},{"issue":"7","key":"536_CR9","first-page":"2427","volume":"118","author":"AG Ramsay","year":"2008","unstructured":"Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest. 2008;118(7):2427\u201337.","journal-title":"J Clin Invest"},{"issue":"9","key":"536_CR10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","volume":"84","author":"L Zhang","year":"2009","unstructured":"Zhang L, Qian Z, Cai Z, Sun L, Wang H, Bartlett JB, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009;84(9):553\u20139.","journal-title":"Am J Hematol"},{"issue":"16","key":"536_CR11","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","volume":"11","author":"FJ Hernandez-Ilizaliturri","year":"2005","unstructured":"Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res. 2005;11(16):5984\u201392.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"536_CR12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","volume":"140","author":"N Reddy","year":"2008","unstructured":"Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140(1):36\u201345.","journal-title":"Br J Haematol"},{"key":"536_CR13","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326\u201335.","journal-title":"Leukemia."},{"issue":"25","key":"536_CR14","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.2014.59.5363","volume":"33","author":"JG Gribben","year":"2015","unstructured":"\u2022\u2022 Gribben JG, Fowler N, Morschhauser F. Mechanisms of action of lenalidomide in B-cell non-Hodgkin lymphoma. J Clin Oncol. 2015;33(25):2803\u201311 Comprehensive review on mechanism of action of lenalidomide and its clinical relevance as therapeutic agent in B-cell non-Hodgkin lymphoma.","journal-title":"J Clin Oncol"},{"key":"536_CR15","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/0008-5472.CAN-06-2317","volume":"67","author":"D Verhelle","year":"2007","unstructured":"Verhelle D, Corral LG, Wong K, Mueller JH, Moutouh-de Parseval L, Jensen-Pergakes K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res. 2007;67:746\u201355.","journal-title":"Cancer Res"},{"key":"536_CR16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/j.1365-2141.2007.06937.x","volume":"140","author":"SM Smith","year":"2008","unstructured":"Smith SM, Grinblatt D, Johnson JL, Niedzwiecki D, Rizzieri D, Bartlett NL, et al. Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. Br J Haematol. 2008;140:313\u20139.","journal-title":"Br J Haematol"},{"key":"536_CR17","unstructured":"Chanan-Khan A, Miller KC, Takeshita K, et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood."},{"issue":"supplement","key":"536_CR18","doi-asserted-by":"crossref","first-page":"6640","DOI":"10.1200\/jco.2005.23.16_suppl.6640","volume":"23","author":"RR Furman","year":"2005","unstructured":"Furman RR, Leonard JP, Allen SL, Coleman M, Rosenthal T, Gabrilove JL. Thalidomide alone or in combination with fludarabine are effective treatments for patients with fludarabine-relapsed and refractory CLL. J Clin Oncol. 2005 ASCO Annual Meeting Proceedings 2005;23(supplement):6640.","journal-title":"J Clin Oncol"},{"key":"536_CR19","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","volume":"104","author":"H Kaufmann","year":"2004","unstructured":"Kaufmann H, Raderer M, Wohrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma. Blood. 2004;104:2269\u201371.","journal-title":"Blood."},{"key":"536_CR20","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1002\/cncr.25055","volume":"116","author":"J Ruan","year":"2010","unstructured":"Ruan J, Martin P, Coleman M, Furman RR, Cheung K, Faye A, et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer. 2010;116:2655\u201364.","journal-title":"Cancer"},{"issue":"16","key":"536_CR21","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1182\/blood-2018-11-884577","volume":"133","author":"L Zhang","year":"2019","unstructured":"Zhang L, Zhao AL, Duan MH, Li ZY, Cao XX, Feng J, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease. Blood. 2019;133(16):1720\u20138.","journal-title":"Blood"},{"issue":"29","key":"536_CR22","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","volume":"31","author":"A Goy","year":"2013","unstructured":"\u2022 Goy A, Sinha R, Williams ME, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688\u201395 First registration trial of lenalidomide in mantle cell lymphoma, which leads to FDA approval of lenalidomide for R\/R MCL.","journal-title":"J Clin Oncol"},{"issue":"3","key":"536_CR23","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","volume":"17","author":"M Trn\u011bn\u00fd","year":"2016","unstructured":"Trn\u011bn\u00fd M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, et al. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17(3):319\u201331.","journal-title":"Lancet Oncol"},{"issue":"7","key":"536_CR24","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","volume":"13","author":"M Wang","year":"2012","unstructured":"Wang M, Fayad L, Wagner-bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. Lancet Oncol. 2012;13(7):716\u201323.","journal-title":"Lancet Oncol"},{"key":"536_CR25","unstructured":"Zaja F, Ferrero S, Stelitano C, et al. Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi. Haematologica."},{"issue":"3","key":"536_CR26","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","volume":"5","author":"M Jerkeman","year":"2018","unstructured":"Jerkeman M, Eskelund CW, Hutchings M, R\u00e4ty R, Wader KF, Laurell A, et al. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial. Lancet Haematol. 2018;5(3):e109\u201316.","journal-title":"Lancet Haematol"},{"key":"536_CR27","doi-asserted-by":"crossref","first-page":"5404","DOI":"10.1200\/JCO.2008.21.1169","volume":"27","author":"T Witzig","year":"2009","unstructured":"Witzig T, Wiernik P, Moore T, Reeder C, Cole C, Justice G, et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2009;27:5404\u20139.","journal-title":"J Clin Oncol"},{"key":"536_CR28","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.12755","volume":"165","author":"J Tuscano","year":"2014","unstructured":"Tuscano J, Dutia M, Chee K, Brunson A, Reed-Pease C, Abedi M, et al. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma. Br J Haematol. 2014;165:375\u201381.","journal-title":"Br J Haematol"},{"key":"536_CR29","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/cncr.28405","volume":"120","author":"T Ahmadi","year":"2014","unstructured":"Ahmadi T, Chong E, Gordon A, Aqui N, Nasta S, Svoboda J, et al. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer. 2014;120:222\u20138.","journal-title":"Cancer"},{"key":"536_CR30","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","volume":"33","author":"J Leonard","year":"2015","unstructured":"Leonard J, Jung S, Johnson J, Pitcher B, Bartlett N, Blum K, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (alliance). J Clin Oncol. 2015;33:3635\u201340.","journal-title":"J Clin Oncol"},{"issue":"14","key":"536_CR31","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1200\/JCO.19.00010","volume":"37","author":"JP Leonard","year":"2019","unstructured":"\u2022 Leonard JP, Trneny M, Izutsu K, Fowler NH, et al. AUGMENT: a phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol. 2019;37(14):1188 The registration trial that led to FDA approval of Len+R for R\/R FL+MZL.","journal-title":"J Clin Oncol"},{"issue":"30","key":"536_CR32","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","volume":"26","author":"PH Wiernik","year":"2008","unstructured":"Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2008;26(30):4952\u20137.","journal-title":"J Clin Oncol"},{"issue":"7","key":"536_CR33","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","volume":"22","author":"TE Witzig","year":"2011","unstructured":"Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin\u2019s lymphoma. Ann Oncol. 2011;22(7):1622\u20137.","journal-title":"Ann Oncol"},{"issue":"15","key":"536_CR34","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","volume":"23","author":"MS Czuczman","year":"2017","unstructured":"Czuczman MS, Trn\u011bn\u00fd M, Davies A, Rule S, Linton KM, Wagner-Johnston N, et al. A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator\u2019s choice in patients with relapsed or refractory diffuse large B-cell lymphoma. Clin Cancer Res. 2017;23(15):4127\u201337.","journal-title":"Clin Cancer Res"},{"key":"536_CR35","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","volume":"27","author":"M Wang","year":"2013","unstructured":"Wang M, Fowler N, Wagner-Bartak N, Feng L, Romaguera J, Neelapu S, et al. Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial. Leukemia. 2013;27:1902\u20139.","journal-title":"Leukemia"},{"issue":"2","key":"536_CR36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/bjh.14049","volume":"174","author":"F Hitz","year":"2016","unstructured":"Hitz F, Zucca E, Pabst T, Fischer N, Cairoli A, Samaras P, et al. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38\/08. Br J Haematol. 2016;174(2):255\u201363.","journal-title":"Br J Haematol"},{"issue":"19","key":"536_CR37","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","volume":"373","author":"J Ruan","year":"2015","unstructured":"Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373(19):1835\u201344.","journal-title":"N Engl J Med"},{"issue":"14","key":"536_CR38","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1182\/blood-2016-03-704023","volume":"128","author":"A Albertsson-Lindblad","year":"2016","unstructured":"Albertsson-Lindblad A, Kolstad A, Laurell A, R\u00e4ty R, Gr\u00f8nb\u00e6k K, Sundberg J, et al. Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. Blood. 2016;128(14):1814\u201320.","journal-title":"Blood"},{"key":"536_CR39","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","volume":"15","author":"N Fowler","year":"2014","unstructured":"Fowler N, Davis R, Rawal S, Nastoupil L, Hagemeister F, Mclaughlin P, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase II trial. Lancet Oncol. 2014;15:1311\u20138.","journal-title":"Lancet Oncol"},{"issue":"11","key":"536_CR40","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1093\/annonc\/mdx496","volume":"28","author":"P Martin","year":"2017","unstructured":"Martin P, Jung SH, Pitcher B, et al. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin\u2019s lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol. 2017;28(11):2806\u201312.","journal-title":"Ann Oncol"},{"issue":"10","key":"536_CR41","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, et al. Rituximab plus Lenalidomide in advanced untreated follicular lymphoma. N Engl J Med. 2018;379(10):934\u201347.","journal-title":"N Engl J Med"},{"issue":"9","key":"536_CR42","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(18)30131-5","volume":"5","author":"H Tilly","year":"2018","unstructured":"Tilly H, Morschhauser F, Casasnovas O, Molina TJ, Feugier P, Gouill SL, et al. Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study. Lancet Haematol. 2018;5(9):e403\u201310.","journal-title":"Lancet Haematol"},{"key":"536_CR43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","volume":"33","author":"GS Nowakowski","year":"2014","unstructured":"Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non\u2013germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin Oncol. 2014;33:251\u20137. https:\/\/doi.org\/10.1200\/JCO.2014.55.5714 .","journal-title":"J Clin Oncol"},{"key":"536_CR44","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","volume":"15","author":"U Vitolo","year":"2014","unstructured":"Vitolo U, et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diff use large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol. 2014;15:730\u20137. https:\/\/doi.org\/10.1016\/S1470-2045(14)70191-3 .","journal-title":"Lancet Oncol"},{"key":"536_CR45","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/ajh.24797","volume":"92","author":"JM Vose","year":"2017","unstructured":"Vose JM. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017;92:806\u201313.","journal-title":"Am J Hematol"},{"key":"536_CR46","doi-asserted-by":"crossref","unstructured":"Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano JM (2009) Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell.","DOI":"10.1111\/j.1365-2141.2009.07626.x"},{"issue":"19","key":"536_CR47","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1182\/blood-2018-07-859769","volume":"132","author":"J Ruan","year":"2018","unstructured":"\u2022 Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, et al. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018;132(19):2016\u201325 Long-term follow-up of the first chemo-free regimen (R2) as initial treatment for MCL.","journal-title":"Blood"},{"issue":"19","key":"536_CR48","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1182\/blood-2018-09-875203","volume":"132","author":"K Maddocks","year":"2018","unstructured":"Maddocks K. Chemotherapy-free induction in MCL: ready for prime time? Blood. 2018;132(19):2001\u20132.","journal-title":"Blood"},{"issue":"Suppl 1","key":"536_CR49","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1182\/blood-2018-99-120069","volume":"132","author":"A Kumar","year":"2018","unstructured":"Kumar A, Zelenetz AD, Batlevi CL, Caron P, Dogan A, Drullinsky P, et al. Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma. Blood. 2018;132(Suppl 1):2880.","journal-title":"Blood"},{"issue":"14","key":"536_CR50","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood-2018-05-853499","volume":"132","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Salles G, Le Gouill S, Tilly H, Thieblemont C, Bouabdallah K, et al. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed\/refractory follicular B-cell lymphoma. Blood. 2018;132(14):1486\u201394.","journal-title":"Blood"},{"issue":"21","key":"536_CR51","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1182\/blood-2016-06-718106","volume":"128","author":"CS Ujjani","year":"2016","unstructured":"Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, et al. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. 2016;128(21):2510\u20136. https:\/\/doi.org\/10.1182\/blood-2016-06-718106 .","journal-title":"Blood"},{"key":"536_CR52","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/leu.2012.172","volume":"27","author":"H Tilly","year":"2013","unstructured":"Tilly H, Morschhauser F, Salles G, Casasnovas R, Feugier P, Molina T, et al. Phase Ib study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia. 2013;27:252\u20135.","journal-title":"Leukemia"},{"issue":"4","key":"536_CR53","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342.","journal-title":"N Engl J Med"},{"issue":"25","key":"536_CR54","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937\u201347.","journal-title":"N Engl J Med"},{"issue":"22","key":"536_CR55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood.V128.22.473.473","volume":"128","author":"A Goy","year":"2016","unstructured":"Goy A, Ramchandren R, Ghosh N, Munoz J, Morgan DS, Dang NH, et al. A multicenter open-label, phase 1b\/2 study of ibrutinib in combination with lenalidomide and rituximab in patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL). Blood. 2016;128(22):473.","journal-title":"Blood"},{"issue":"Suppl 1","key":"536_CR56","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood-2018-99-111163","volume":"132","author":"R Ramchandren","year":"2018","unstructured":"Ramchandren R, Johnson P, Ghosh N, Ruan J, Ardeshna KM, Johnson R, et al. The iR2 regimen (ibrutinib, lenalidomide, and rituximab) is active with a manageable safety profile in patients with relapsed\/refractory non-germinal center-like diffuse large B-cell lymphoma. Blood. 2018;132(Suppl 1):402.","journal-title":"Blood"},{"key":"536_CR57","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/bjh.13945","volume":"173","author":"A Mart\u00edn","year":"2016","unstructured":"Mart\u00edn A, Redondo AM, Dlouhy I, Salar A, Gonz\u00e1lez-Barca E, Canales M, et al. Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group. Br J Haematol. 2016;173:245\u201352.","journal-title":"Br J Haematol"},{"issue":"1","key":"536_CR58","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.12846","volume":"166","author":"T Feldman","year":"2014","unstructured":"Feldman T, Mato AR, Chow KF, Protomastro EA, Yannotti KML, Bhattacharyya P, et al. Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse\/primary refractory diffuse large B-cell lymphoma. Br J Haematol. 2014;166(1):77\u201383.","journal-title":"Br J Haematol"},{"key":"536_CR59","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","volume":"160","author":"LH Zhang","year":"2013","unstructured":"Zhang LH, Kosek J, Wang M, Heise C, Schafer PH, Chopra R. Lenalidomide efficacy in activated b-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol. 2013;160:487\u2013502.","journal-title":"Br J Haematol"},{"issue":"11","key":"536_CR60","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s41408-018-0145-9","volume":"8","author":"A Castellino","year":"2018","unstructured":"Castellino A, Chiappella A, LaPlant BR, et al. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. Blood Cancer J. 2018;8(11):108. Published 2018 Nov 8. https:\/\/doi.org\/10.1038\/s41408-018-0145-9 .","journal-title":"Blood Cancer J"},{"issue":"7","key":"536_CR61","first-page":"10705","volume":"8","author":"C Fang","year":"2015","unstructured":"Fang C, Zhu D, Dong H, et al. Lenalidomide alone or in combination with chemotherapy treatment for subtypes of diffuse large B cell lymphoma: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8(7):10705\u201313 Published 2015 Jul 15.","journal-title":"Int J Clin Exp Med"},{"issue":"13","key":"536_CR62","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","volume":"12","author":"GS Nowakowski","year":"2016","unstructured":"Nowakowski GS, Chiappella A, Witzig TE, Spina M, Gascoyne RD, Zhang L, et al. ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Future Oncol. 2016;12(13):1553\u201363.","journal-title":"Future Oncol"},{"key":"536_CR63","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/hon.5_2629","volume":"37","author":"U Vitolo","year":"2019","unstructured":"Vitolo U, Witzig T, Gascoyne R, et al. ROBUST: first report of phase III randomized study of lenalidomide\/R-CHOP (R2-CHOP) vs placebo\/R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. Hematol Oncol. 2019;37:36\u20137.","journal-title":"Hematol Oncol"},{"key":"536_CR64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hon.6_2629","volume":"37","author":"G Nowakowski","year":"2019","unstructured":"Nowakowski G, Hong F, Scott D, et al. Addition of lenalidomide to R-CHOP (R2CHOP) improves outcomes in newly diagnosed diffuse large b-cell lymphoma (dlbcl): first report of ECOG-ACRIN1412 a randomized phase 2 US intergroup study of R2CHOP vs R-CHOP. Hematol Oncol. 2019;37:37\u20138.","journal-title":"Hematol Oncol"},{"issue":"22","key":"536_CR65","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","volume":"35","author":"C Thieblemont","year":"2017","unstructured":"Thieblemont C, Tilly H, Gomes da silva M, et al. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2017;35(22):2473\u201381.","journal-title":"J Clin Oncol"},{"issue":"3","key":"536_CR66","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1016\/S2352-3026(17)30016-9","volume":"4","author":"AJ Ferreri","year":"2017","unstructured":"Ferreri AJ, Sassone M, Zaja F, et al. Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial. Lancet Haematol. 2017;4(3):e137\u201346.","journal-title":"Lancet Haematol"},{"issue":"4","key":"536_CR67","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1159\/000484515","volume":"138","author":"R Dada","year":"2017","unstructured":"Dada R. Lenalidomide maintenance after R-CHOP therapy in diffuse large B-cell lymphoma: can it be a standard of care. Acta Haematol. 2017;138(4):216\u201320.","journal-title":"Acta Haematol"},{"key":"536_CR68","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375\u201390.","journal-title":"Blood"},{"issue":"3","key":"536_CR69","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(15)00284-7","volume":"3","author":"M Ogura","year":"2016","unstructured":"Ogura M, Imaizumi Y, Uike N, Asou N, Utsunomiya A, Uchida T, et al. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. Lancet Haematol. 2016;3(3):e107\u201318.","journal-title":"Lancet Haematol"},{"issue":"34","key":"536_CR70","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1200\/JCO.2016.67.7732","volume":"34","author":"T Ishida","year":"2016","unstructured":"Ishida T, Fujiwara H, Nosaka K, Taira N, Abe Y, Imaizumi Y, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia\/lymphoma: ATLL-002. J Clin Oncol. 2016;34(34):4086\u201393.","journal-title":"J Clin Oncol"},{"issue":"34","key":"536_CR71","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2016.69.4505","volume":"34","author":"N Mehta-shah","year":"2016","unstructured":"Mehta-shah N, Horwitz SM. Lenalidomide in adult T-cell leukemia\/lymphoma. J Clin Oncol. 2016;34(34):4066\u20137.","journal-title":"J Clin Oncol"},{"issue":"13","key":"536_CR72","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1016\/j.ejca.2013.04.029","volume":"49","author":"F Morschhauser","year":"2013","unstructured":"Morschhauser F, Fitoussi O, Haioun C, Thieblemont C, Quach H, Delarue R, et al. A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. Eur J Cancer. 2013;49(13):2869\u201376.","journal-title":"Eur J Cancer"},{"issue":"5","key":"536_CR73","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","volume":"121","author":"E Toumishey","year":"2015","unstructured":"Toumishey E, Prasad A, Dueck G, Chua N, Finch D, Johnston J, et al. Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma. Cancer. 2015;121(5):716\u201323.","journal-title":"Cancer"},{"issue":"8","key":"536_CR74","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2013-09-525915","volume":"123","author":"C Querfeld","year":"2014","unstructured":"Querfeld C, Rosen ST, Guitart J, Duvic M, Kim YH, Dusza SW, et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and S\u00e9zary syndrome. Blood. 2014;123(8):1159\u201366.","journal-title":"Blood"},{"issue":"3","key":"536_CR75","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1684\/ejd.2017.3008","volume":"27","author":"M Bagot","year":"2017","unstructured":"Bagot M, Hasan B, Whittaker S, Beylot-Barry M, Knobler R, Shah E, et al. A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. Eur J Dermatol. 2017;27(3):286\u201394.","journal-title":"Eur J Dermatol"},{"issue":"6","key":"536_CR76","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1182\/blood-2015-02-628669","volume":"126","author":"PR Hagner","year":"2015","unstructured":"Hagner PR, Man HW, Fontanillo C, Wang M, Couto S, Breider M, et al. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood. 2015;126(6):779\u201389.","journal-title":"Blood."},{"issue":"Suppl 1","key":"536_CR77","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/blood-2018-99-110213","volume":"132","author":"J Michot","year":"2018","unstructured":"Michot J, Bouabdallah R, Doorduijn JK, Vitolo U, Kersten MJ, Chiappella A, et al. Avadomide (CC-122), a novel cereblon modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Blood. 2018;132(Suppl 1):449.","journal-title":"Blood"},{"issue":"Suppl 1","key":"536_CR78","first-page":"411","volume":"130","author":"J Michot","year":"2017","unstructured":"Michot J, Bouabdallah R, Doorduijn JK, Vitolo U, Kersten MJ, Chiappella A, et al. CC-122, a novel cereblon modulating agent, in combination with obinutuzumab (GA101) in patients with relapsed and refractory (R\/R) B-cell non-Hodgkin lymphoma (NHL). Blood. 2017;130(Suppl 1):411.","journal-title":"Blood"},{"issue":"Suppl 1","key":"536_CR79","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1182\/blood-2018-99-114409","volume":"132","author":"LJ Nastoupil","year":"2018","unstructured":"Nastoupil LJ, Bijou F, Ribrag V, Chavez JC, Witzig TE, Andorsky DJ, et al. Avadomide (CC-122), a novel cereblon modulating agent, plus rituximab in patients with relapsed or refractory follicular lymphoma. Blood. 2018;132(Suppl 1):1602.","journal-title":"Blood"},{"issue":"Suppl 1","key":"536_CR80","first-page":"1551","volume":"130","author":"V Ribrag","year":"2017","unstructured":"Ribrag V, Chavez JC, Vitolo U, Kaplan JB, Chandler JC, Santoro A, et al. CC-122 DLBCL-001: phase Ib study of CC-122 plus rituximab in patients with chemo-refractory diffuse large B-cell lymphoma (DLBCL). Blood. 2017;130(Suppl 1):1551.","journal-title":"Blood"},{"issue":"7","key":"536_CR81","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1093\/annonc\/mdw158","volume":"27","author":"J Ruan","year":"2016","unstructured":"Ruan J, Shah B, Martin P, Schuster SJ. Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas. Ann Oncol. 2016;27(7):1226\u201334.","journal-title":"Ann Oncol"},{"issue":"8","key":"536_CR82","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1093\/annonc\/mdv102","volume":"26","author":"TE Witzig","year":"2015","unstructured":"Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, et al. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma. Ann Oncol. 2015;26(8):1667\u201377.","journal-title":"Ann Oncol"},{"key":"536_CR83","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327:1345\u201350.","journal-title":"Science"},{"issue":"6","key":"536_CR84","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1200\/JCO.2014.59.7351","volume":"33","author":"GH Lyman","year":"2015","unstructured":"Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update 2014. J Clin Oncol. 2015;33(6):654\u20136.","journal-title":"J Clin Oncol"},{"issue":"12","key":"536_CR85","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/bloodadvances.2018016683","volume":"2","author":"S Yamshon","year":"2018","unstructured":"Yamshon S, Christos PJ, Demetres M, Hammad H, Leonard JP, Ruan J. Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis. Blood Adv. 2018;2(12):1429\u201338.","journal-title":"Blood Adv"},{"issue":"6","key":"536_CR86","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","volume":"164","author":"AK Gandhi","year":"2013","unstructured":"Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN). Br J Haematol. 2013;164(6):811\u201321.","journal-title":"Br J Haematol"},{"issue":"4","key":"536_CR87","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/bjh.13456","volume":"170","author":"A Goy","year":"2015","unstructured":"Goy A, Kalayoglu Besisik S, Drach J, Ramchandren R, Robertson MJ, Avivi I, et al. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed\/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. Br J Haematol. 2015;170(4):496\u2013503.","journal-title":"Br J Haematol"},{"key":"536_CR88","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","volume":"111","author":"O Determann","year":"2008","unstructured":"Determann O, Hoster E, Ott G, Wolfram Bernd H, Loddenkemper C, Leo Hansmann M, et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood. 2008;111:2385\u20137.","journal-title":"Blood"},{"issue":"3","key":"536_CR89","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","volume":"97","author":"F Zaja","year":"2012","unstructured":"Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica. 2012;97(3):416\u201322.","journal-title":"Haematologica"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00536-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-019-00536-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-019-00536-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T23:15:13Z","timestamp":1721517313000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-019-00536-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,13]]},"references-count":89,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["536"],"URL":"https:\/\/doi.org\/10.1007\/s11899-019-00536-6","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,13]]},"assertion":[{"value":"13 July 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Samuel Yamshon declares that he has no conflict of interest. Jia Ruan reports grants and personal fees from Celgene, grants from Pharmacyclics, grants and personal fees from AstraZeneca, grants from Seattle Genetics, personal fees from Juno Therapeutics, and personal fees from Kite Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}